PsyMed Ventures is a venture capital firm focused on investing in early-stage, frontier technologies that aim to transform brain and mental health. Their strategy involves supporting innovative solutions across areas like neurotech, precision neuroscience, novel therapeutics, digital therapeutics, AI, and psychedelic medicine, with a mission to align healing, responsibility, and profitability.
50% of their portfolio is in Healthcare. They made 1 investments in the last 12 months. Their most common stage is series-a (50% of deals). Average disclosed round size is $25.6M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$14.7M
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Aerska | Seed | $21M | Oct 2025 |
 Journey Clinical | Series A | $8.5M | Jan 2023 |
 Delix Therapeutics | Series A | $70M | Sep 2021 |
| Journey Clinical | Seed | $3M | Sep 2021 |
Top Co-Investors
Palo Santo3 shared
Fifty Years2 shared
RA Capital Management1 shared
Apeiron Investment Group1 shared
Casa Verde Capital1 shared
Dolby Family Ventures1 shared
Presight Capital1 shared
The Vertical Group1 shared
Union Square Ventures1 shared
AlleyCorp1 shared
Able Partners1 shared
Gaingels1 shared
Coalition1 shared
Speedinvest1 shared
age11 shared
BlueYard Capital1 shared
Exor Ventures1 shared
Norrsken VC1 shared
Last updated: 12 April 2026